이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)

2014년 3월 12일 업데이트: Clovis Oncology, Inc.

A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma

The purpose of this study is to determine whether CO-1.01 is safe and effective in the treatment of patients with metastatic pancreatic cancer and low hENT1 expression compared with gemcitabine.

연구 개요

상세 설명

Pancreatic cancer is a very serious form of cancer. The majority of patients present with unresectable disease, and the condition is often not diagnosed until the cancer is relatively advanced. The standard first-line treatment for patients with unresectable pancreatic cancer is gemcitabine monotherapy. Unfortunately many of these patients fail to derive benefit from this treatment. No clinical or molecular marker has been established to predict benefit from gemcitabine therapy, so patients are treated empirically until evidence of disease progression or worsening performance status.

The potential for human equilibrative nucleoside transporter-1 (hENT1) expression to predict survival in gemcitabine-treated patients has been studied, and data suggest that patients with low levels of tumor cell hENT1 expression derive less benefit from gemcitabine treatment than patients with high levels of tumor cell hENT1 expression. These data support the hypothesis to be tested in this study that patients with pancreatic tumors expressing low levels of hENT1 will derive minimal benefit from gemcitabine, but will receive benefit from CO-1.01 (gemcitabine elaidate) which enters tumor cells in a hENT1-independent fashion.

연구 유형

중재적

등록 (실제)

367

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Noord-Holland
      • Amsterdam, Noord-Holland, 네덜란드, 1081 HV
        • Vrije Universiteit Medisch Centrum
      • Kristiansand, 노르웨이, 4604
        • Sørlandet Sykehus HF
      • Oslo, 노르웨이, 0407
        • Oslo universitetssykehus, Ullevål
      • Berlin, 독일, 13353
        • Charité Universitätsmedizin Berlin
      • Dresden, 독일, 01307
        • Universitatsklinikum Carl Gustav Carus
      • Magdeburg, 독일, 39120
        • Klinik der Otto-Von-Guericke-Universität Magdeburg
      • Ulm, 독일, 89081
        • Medizinische Universitätsklinik Ulm, Abt. Innere Medizin I
    • Bayern
      • München, Bayern, 독일, 81377
        • Ludwig-Maximilians-Universität, Medizinische Klinik und Poliklinikversität München
    • Mecklenburg-Vorpommern
      • Greifswald, Mecklenburg-Vorpommern, 독일, 17475
        • Klinikum der Ernst-Moritz-Arndt-Universität
    • Nordrhein-Westfalen
      • Bochum, Nordrhein-Westfalen, 독일, 44892
        • Knappschaftskrankenhaus Bochum-Langendreer
    • Thueringen
      • Jena, Thueringen, 독일, 07740
        • Universitatsklinikum Jena
      • Ekaterinburg, 러시아 연방, 620036
        • Sverdlovsk Regional Oncology Center
      • Irkutsk, 러시아 연방, 664035
        • Regional Oncology Center
      • Krasnodar, 러시아 연방, 350040
        • Clinical Oncology Center #1
      • Kursk, 러시아 연방, 305035
        • Kursk Regional Oncology Center
      • Moscow, 러시아 연방, 115478
        • Blokhin Cancer Research Center
      • Novosibirsk, 러시아 연방, 630047
        • Novosibirsk, City Clinical Hospital #1
      • St. Petersburg, 러시아 연방, 194291
        • Leningrad Regional Clinical Hospital
      • St. Petersburg, 러시아 연방, 195067
        • Mechnikov St. Petersburg State Medical Academy
      • St. Petersburg, 러시아 연방, 197785
        • St. Petersburg City Oncology Center
      • Tambov, 러시아 연방, 392013
        • Tambov Regional Oncology Center
      • Tula, 러시아 연방, 300053
        • Tula Regional Oncology Center
      • Yaroslavl, 러시아 연방, 150040
        • Regional Clinical Oncology Hospital
    • Republic of Udmurtia
      • Izhevsk, Republic of Udmurtia, 러시아 연방, 426067
        • Republic Clinical Oncology Center
    • Arizona
      • Glendale, Arizona, 미국, 85306
        • Arizona Center for Hematology Oncology
    • California
      • Corona, California, 미국, 92879
        • Wilshire Oncology Medical Group, Inc.
      • Los Angeles, California, 미국, 90033
        • White Memorial Medical Center
      • Los Angeles, California, 미국, 90036
        • Cancer Care Institute
      • Newport Beach, California, 미국, 92660
        • Newport Cancer Care Medical
      • Oakland, California, 미국, 94609
        • Hematology Oncology Associates
      • San Diego, California, 미국, 92123
        • Sharp Clinical Oncology Research
    • Colorado
      • Denver, Colorado, 미국, 80218
        • Rocky Mountain Cancer Centers
    • Connecticut
      • Hartford, Connecticut, 미국, 06102
        • Hartford Hospital Clinical Research
      • Trumbull, Connecticut, 미국, 06611
        • Oncology Associates of Bridgeport
    • Maryland
      • Annapolis, Maryland, 미국, 21401
        • Annapolis Oncology Center
    • Minnesota
      • Minneapolis, Minnesota, 미국, 55407
        • Virginia Piper Cancer Institute
    • New Jersey
      • New Brunswick, New Jersey, 미국, 08901
        • The Cancer Institute of New Jersey
    • New Mexico
      • Albuquerque, New Mexico, 미국, 87109
        • New Mexico Cancer Care Alliance
    • New York
      • Lake Success, New York, 미국, 11042
        • Arena Oncology Associates, PC
    • Oregon
      • Bend, Oregon, 미국, 97701
        • Bend Memorial Clinic
    • South Carolina
      • Greenville, South Carolina, 미국, 29605
        • Cancer Center Of The Carolinas
    • Texas
      • Corpus Christi, Texas, 미국, 78412
        • Cancer Specialists of South Texas, P.A.
      • Harlingen, Texas, 미국, 78550
        • Valley Cancer Associates
      • San Antonio, Texas, 미국, 78229
        • South Texas Oncology and Hematology, PA
    • Wisconsin
      • Milwaukee, Wisconsin, 미국, 53226
        • Medical College of Wisconsin
      • Brussels, 벨기에, 1200
        • Cliniques Universitaires Saint Luc
      • Haine-Saint-Paul, 벨기에, 7100
        • Centre Hospitalier de Jolimont-Lobbes
    • Antwerpen
      • Edegem, Antwerpen, 벨기에, 2650
        • Universitair Ziekenhuis Antwerpen
      • Rio de Janeiro, 브라질, 20231
        • Instituto Nacional do Câncer
    • Distrito Federal
      • Brasilia, Distrito Federal, 브라질, 70840
        • Hospital Universitario
    • Minas Gerais
      • Belo Horizonte, Minas Gerais, 브라질, 60430-230
        • Santa Casa de Misericordia de Belo Horizonte
    • Rio Grande Do Sul
      • Porto Alegre, Rio Grande Do Sul, 브라질, 90610-000
        • Hospital Sao Lucas - PUCRS
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, 브라질, 90020
        • Irmandade da Santa
    • Santa Catarina
      • Florianópolis, Santa Catarina, 브라질, 88034-000
        • CEPON-Centro de Pesquisas Oncológicas
    • Sao Paulo
      • Barretos, Sao Paulo, 브라질, 14784-400
        • Hospital do Cancer de Barretos
      • Jau, Sao Paulo, 브라질, 17210
        • Fundacao Hospital
      • Santo Andre, Sao Paulo, 브라질, 09060-650
        • Faculdade de Medicina do ABC
      • Jonkoping, 스웨덴, 551 85
        • Länssjukhuset Ryhov
      • Linköping, 스웨덴, 581 85
        • Linköping University Hospital
      • Växjö, 스웨덴, 351 85
        • Växjö Centrallasarettet
      • Córdoba, 아르헨티나, X5004FHP
        • Clínica Universitaria Reina Fabiola
      • Santa Fe, 아르헨티나, S3000FFU
        • ISIS Centro especializado
    • Bahia Blanca
      • Buenos Aires, Bahia Blanca, 아르헨티나, B8000FJI
        • Policlínica Privada Instituto de Medicina Nuclear
    • Buenos Aires
      • Cuidad Autónoma de Buenos Aires, Buenos Aires, 아르헨티나, C1426ANZ
        • Instituto Especializado Alexander Fleming
      • Loma Hermosa, Buenos Aires, 아르헨티나, B1657BHD
        • Hospital de Gastroenterología
    • England
      • London, England, 영국, W12 0HS
        • Hammersmith Hospital
      • Manchester, England, 영국, M20 4BX
        • Christie Hospital
    • Scotland
      • Glasgow, Scotland, 영국, G12 0YN
        • Beatson West of Scotland Cancer Centre, Cancer Research UK Clinical Trials Unit (CTU)
      • Dnipropetrovsk, 우크라이나, 49102
        • Dnipropetrovsk City Multispecialty Clinical Hospital #4, Department of Chemotherapy, Dnipropetrovsk State Medical Academy, Department of Oncology and Medical Radiology
      • Donetsk, 우크라이나, 83092
        • Public Clinical Treatment and Prophylaxis Institution "Donetsk Regional Antitumor Center", Oncosurgery Department #6
      • Kharkiv, 우크라이나, 61070
        • "Public Healthcare Institution ""Kharkiv Regional Clinical Oncology Center"", Abdominal Department
      • Kiev, 우크라이나, 03022
        • National Cancer Institute, Department of Tumors of Abdominal Cavity and Retroperitoneum
      • Lviv, 우크라이나, 79031
        • State Regional Diagnostics and Treatment Oncology Center, Chemotherapy Department
      • Mykolayiv, 우크라이나, 54044
        • Mykolayiv Regional Oncology Center, Surgery Department #1
      • Uzhorod, 우크라이나, 88014
        • Zakarpatya Regional Clinical Oncology Center, Chemotherapy Department
      • Zaporizhya, 우크라이나, 69032
        • Clinical Facility: Public Institution "Zaporizhya City Clinical Hospital #3", Regional Center of Hepatic, Biliary Tract and Pancreatic Surgery, Surgery Department #1
      • Milano, 이탈리아, 20132
        • Fondazione San Raffaele del Monte Tabor
      • Padova, 이탈리아, 35128
        • Instituto Oncologico Veneto, Oncologia Medica 1
      • Torrette di Ancona, 이탈리아, 60020
        • Ospedali Riuniti di Ancona
      • Verona, 이탈리아, 37134
        • Centro Ricerche Cliniche Di Verona
    • Emilia-Romagna
      • Bologna, Emilia-Romagna, 이탈리아, 40138
        • Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi
    • Alberta
      • Edmonton, Alberta, 캐나다, T6G 1Z2
        • Cross Cancer Institute
      • Bayonne Cedex, 프랑스, 64109
        • Centre Hospitalier de la Côte Basque
      • Bordeaux, 프랑스, 33000
        • Hôpital Saint André, Service d'Oncologie Médicale
      • Limoges Cedex, 프랑스, 87039
        • Clinique Francois Chenieux
      • Montpellier, 프랑스, 34298
        • Centre Regional de Lutte contre le Cancer Val d'Aurelle
      • Montpellier Cedex 5, 프랑스, 34295
        • Centre Hospitalier Régional Universitaire Hôpital Saint Eloi
      • Saint Herblain cedex, 프랑스, 44805
        • Centre Rene Gauducheau
      • Villejuif Cedex, 프랑스, 94805
        • Institut Gustave-Roussy - Centre de Lutte Contre le Cancer
    • New South Wales
      • New Lambton Heights, New South Wales, 호주, 2305
        • Newcastle Private Hospital
      • Port Macquarie, New South Wales, 호주, 2444
        • Port Macquarie Base Hospital
      • Wollongong, New South Wales, 호주, 2500
        • Southern Medical Day Oncology Care Centre
    • South Australia
      • Bedford Park, South Australia, 호주, 5042
        • Flinders Medical Centre
    • Victoria
      • Fitzroy, Victoria, 호주, 3065
        • Saint Vincent's Hospital
      • Wodonga, Victoria, 호주, 3690
        • Border Medical Oncology, Murray Valley Private Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Metastatic pancreatic ductal adenocarcinoma (i.e., Stage 4).
  • Histological/cytological confirmation of metastatic tissue (not primary tumor) by a central pathology laboratory (H&E stain) to ensure sufficient material is available for later hENT1 analysis.
  • Adjuvant chemotherapy/radiotherapy ≥ 6 months prior to randomization.
  • Palliative radiotherapy (if administered) ≥ 1 month prior to randomization.
  • CT scan ≤30 days prior to randomization
  • Performance Status (ECOG) 0 or 1.
  • Estimated life expectancy ≥ 12 weeks.
  • Age ≥ 18 years.
  • Adequate hematological and biological function.
  • Written consent on an Institutional Review Board/Institutional Ethics Committee-approved Informed Consent Form prior to any study-specific evaluation.

Exclusion Criteria:

  • Prior palliative chemotherapy for pancreatic cancer.
  • Radical pancreatic resections (e.g., Whipple procedure) are not allowed < 6 months prior to randomization. Exploratory laparotomy, palliative (e.g., bypass) surgery, or other procedures (e.g., stents) are not allowed < 14 days prior to randomization. In both cases the patient must be sufficiently recovered and stable.
  • Symptomatic brain metastases.
  • Participation in other investigational drug clinical studies ≤ 30 days prior to randomization.
  • Concomitant treatment with prohibited medications.
  • History of allergy to gemcitabine or eggs.
  • Presence of any serious or unstable concomitant systemic disorder incompatible with the clinical study (e.g., substance abuse, uncontrolled intercurrent illness including active infection, arterial thrombosis, symptomatic pulmonary embolism).
  • Any disorder that would hamper protocol compliance.
  • Prior nonpancreatic malignancy treated with chemotherapy. Prior malignancies treated with surgery or radiotherapy alone must be in remission ≥ 3 years. The following prior malignancies are allowable irrespective of when they occurred: in situ carcinoma of the cervix, in situ ductal breast cancer, low-grade local bladder cancer, and nonmelanotic skin cancer.
  • Females who are pregnant or breastfeeding.
  • Refusal to use adequate contraception for fertile patients (females and males during the study and for 6 months after the last study treatment). Adequate forms of contraception are double-barrier methods (condoms or diaphragm with spermicidal jelly or foam); oral, depot, or injectable contraceptives; intrauterine devices; tubal ligation.
  • Any other reason the investigator considers the patient should not participate in the study.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: 젬시타빈
1000 mg/m2 intravenous infusion weekly for 7 weeks followed by 1 week rest, then weekly for 3 weeks every 4 weeks
실험적: CO-1.01
1250 mg/m2 intravenous infusion weekly for 3 weeks every 4 weeks

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
기간
Overall Survival in Patients With Low High Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression
기간: Monthly follow up after treatment discontinuation until death, up to 1.5 years.
Monthly follow up after treatment discontinuation until death, up to 1.5 years.

2차 결과 측정

결과 측정
기간
Overall Survival in All Patients and Patients With hENT1 Expression
기간: Monthly follow up after treatment discontinuation until death, up to 1.5 years
Monthly follow up after treatment discontinuation until death, up to 1.5 years
ORR, Duration of Response, and Progression Free Survival (PFS) in Patients With Measurable/Evaluable Disease, Using RECIST 1.1, up to 1.5 Years
기간: Every 8 weeks
Every 8 weeks
Cancer Antigen (CA)19-9 Response Rates
기간: Every 4 weeks, up to 1.5 years
Every 4 weeks, up to 1.5 years
Drug Tolerability and Toxicity
기간: Every week, up to 1.5 years
Every week, up to 1.5 years
Change From Baseline in Pain Severity
기간: Every 4 weeks, up to 1.5 years
Every 4 weeks, up to 1.5 years
Change From Baseline in Health Status
기간: Every 4 weeks, up to 1.5 years
Every 4 weeks, up to 1.5 years
Pharmacokinetic (PK) Profile of CO-1.01 Based on Sparse Sampling
기간: 30 days after first dose
30 days after first dose

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2010년 5월 1일

기본 완료 (실제)

2012년 11월 1일

연구 완료 (실제)

2013년 6월 1일

연구 등록 날짜

최초 제출

2010년 5월 12일

QC 기준을 충족하는 최초 제출

2010년 5월 14일

처음 게시됨 (추정)

2010년 5월 17일

연구 기록 업데이트

마지막 업데이트 게시됨 (추정)

2014년 4월 17일

QC 기준을 충족하는 마지막 업데이트 제출

2014년 3월 12일

마지막으로 확인됨

2014년 3월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다